AbbVie Inc.

Symbol: 4AB.DE

XETRA

149.2

EUR

Market price today

  • 47.3873

    P/E Ratio

  • -0.8646

    PEG Ratio

  • 263.47B

    MRK Cap

  • 0.04%

    DIV Yield

AbbVie Inc. (4AB-DE) Stock Price & Analysis

Shares Outstanding

0M

Gross Profit Margin

0.62%

Operating Profit Margin

0.24%

Net Profit Margin

0.11%

Return on Assets

0.04%

Return on Equity

0.55%

Return on Capital Employed

0.12%

Company general description and statistics

Sector: Healthcare
Industry: Drug Manufacturers - General
CEO:Mr. Richard A. Gonzalez
Full-time employees:50000
City:North Chicago
Address:1 North Waukegan Road
IPO:2016-05-17
CIK:

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

General Outlook

When we look at how much money they make before expenses, they keep 0.623% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is 0.235%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of 0.110%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust 0.040% return, is a testament to AbbVie Inc.'s adeptness in optimizing resource deployment. AbbVie Inc.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 0.553%. Furthermore, the proficiency of AbbVie Inc. in capital utilization is underscored by a remarkable 0.119% return on capital employed.

Liquidity Ratios

Analyzing 4AB.DE liquidity ratios reveals its financial health of the firm. The current ratio of 93.62% gauges short-term asset coverage for liabilities. The quick ratio (72.29%) assesses immediate liquidity, while the cash ratio (43.51%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio93.62%
Quick Ratio72.29%
Cash Ratio43.51%

Profitability Ratios

4AB.DE profitability indicators offer a lens into its earnings landscape. A pretax profit margin of 13.84% underscores its earnings before tax deductions. The effective tax rate stands at 20.27%, revealing its tax efficiency. The net income per EBT, 79.59%, and the EBT per EBIT, 58.89%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of 23.50%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin13.84%
Effective Tax Rate20.27%
Net Income per EBT79.59%
EBT per EBIT58.89%
EBIT per Revenue23.50%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 0.94, it details the span from stock purchase to revenue. The 1 days it takes to settle debts showcases its creditor relations.

cards.indicatorcards.value
Days of Sales Outstanding72
Days of Inventory Outstanding75
Operating Cycle155.67
Cash Conversion Cycle156
Receivables Turnover4.55
Inventory Turnover4.83
Fixed Asset Turnover10.92
Asset Turnover0.37

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, 12.85, and free cash flow per share, 12.40, depict cash generation on a per-share basis. The cash per share value, 10.23, showcases liquidity position. A payout ratio of 1.78 highlights the portion of earnings distributed as dividends. Lastly, the operating cash flow sales ratio, 0.42, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share12.85
Free Cash Flow per Share12.40
Cash per Share10.23
Payout Ratio1.78
Operating Cash Flow Sales Ratio0.42
Free Cash Flow to Operating Cash Flow Ratio0.96
Cash Flow Coverage Ratio0.31
Short Term Coverage Ratio2.22
Capital Expenditure Coverage Ratio28.54
Dividend Paid and Capex Coverage Ratio1.98
Dividend Payout Ratio0.04

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 49.71%, highlights its total liabilities relative to assets. With a debt-equity ratio of 9.24, we discern the balance between debt and equity financing. The long-term debt to capitalization, 88.85%, and total debt to capitalization, 90.24%, ratios shed light on its capital structure. An interest coverage of 5.88 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio49.71%
Debt Equity Ratio9.24
Long Term Debt to Capitalization88.85%
Total Debt to Capitalization90.24%
Interest Coverage5.88
Cash Flow to Debt Ratio0.31
Company Equity Multiplier18.59

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 30.76, provides a glimpse into top-line earnings distributed across each share. Net income per share, 2.75, reflects the portion of profit attributed to each share. The book value per share, 5.87, represents the net asset value distributed per share, while the tangible book value per share, -43.89, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share30.76
Net Income Per Share2.75
Book Value Per Share5.87
Tangible Book Value Per Share-43.89
Shareholders Equity Per Share5.87
Interest Debt Per Share34.89
Capex Per Share-0.44

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, -6.44%, indicates top-line expansion, while the gross profit growth, -16.58%, reveals profitability trends. EBIT growth, 13.98%, and operating income growth, 13.98%, offer insights into operational profitability progression. The net income growth, -58.91%, showcases bottom-line expansion, and the EPS growth, -58.89%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth-6.44%
Gross Profit Growth-16.58%
EBIT Growth13.98%
Operating Income Growth13.98%
Net Income Growth-58.91%
EPS Growth-58.89%
EPS Diluted Growth-58.97%
Weighted Average Shares Growth-0.29%
Weighted Average Shares Diluted Growth-0.28%
Dividends per Share Growth5.24%
Operating Cash Flow Growth-8.44%
Free Cash Flow Growth-9.02%
10-Year Revenue Growth per Share159.85%
5-Year Revenue Growth per Share38.88%
3-Year Revenue Growth per Share18.53%
10-Year Operating CF Growth per Share227.58%
5-Year Operating CF Growth per Share42.44%
3-Year Operating CF Growth per Share29.80%
10-Year Net Income Growth per Share5.89%
5-Year Net Income Growth per Share-28.39%
3-Year Net Income Growth per Share5.30%
10-Year Shareholders Equity Growth per Share107.31%
5-Year Shareholders Equity Growth per Share202.72%
3-Year Shareholders Equity Growth per Share-20.81%
10-Year Dividend per Share Growth per Share270.77%
5-Year Dividend per Share Growth per Share58.16%
3-Year Dividend per Share Growth per Share36.52%
Receivables Growth-0.88%
Inventory Growth14.53%
Asset Growth-2.95%
Book Value per Share Growth-39.78%
Debt Growth-6.14%
R&D Expense Growth17.90%
SGA Expenses Growth-15.65%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 318,850,975,507.182, captures the company's total value, considering both debt and equity. Income quality, 4.69, assesses the reliability of reported earnings. The sales, general, and administrative to revenue ratio, 0.20, gauges operational efficiency, while the research and development to revenue, 14.13%, highlights investment in innovation. The ratio of intangibles to total assets, 65.25%, indicates the value of non-physical assets, and capex to operating cash flow, -3.40%, measures reinvestment capability.

cards.indicatorcards.value
Enterprise Value318,850,975,507.182
Income Quality4.69
Sales General and Administrative to Revenue0.20
Research and Development to Revenue14.13%
Intangibles to Total Assets65.25%
Capex to Operating Cash Flow-3.40%
Capex to Revenue-1.43%
Capex to Depreciation-8.93%
Stock-Based Compensation to Revenue1.38%
Graham Number19.07
Return on Tangible Assets10.39%
Graham Net Net-57.24
Working Capital-4,839,000,000
Tangible Asset Value-77,506,000,000
Net Current Asset Value-91,312,000,000
Invested Capital6
Average Receivables11,204,500,000
Average Payables3,311,000,000
Average Inventory3,839,000,000
Days Sales Outstanding75
Days Payables Outstanding66
Days of Inventory On Hand73
ROIC14.26%
ROE0.47%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 35.47, and the price to book ratio, 35.47, reflect the market's valuation relative to the company's book value. The price to sales ratio, 5.22, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, 12.97, and price to operating cash flows, 12.52, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio35.47
Price to Book Ratio35.47
Price to Sales Ratio5.22
Price Cash Flow Ratio12.52
Price Earnings to Growth Ratio-0.86
Enterprise Value Multiple13.91
Price Fair Value35.47
Price to Operating Cash Flow Ratio12.52
Price to Free Cash Flows Ratio12.97
Price to Tangible Book Ratio26.28
Enterprise Value to Sales5.87
Enterprise Value Over EBITDA17.62
EV to Operating Cash Flow13.96
Earnings Yield1.79%
Free Cash Flow Yield8.10%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of AbbVie Inc. (4AB.DE) on the XETRA in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is 47.387 in 2024.

What is the ticker symbol of AbbVie Inc. stock?

The ticker symbol of AbbVie Inc. stock is 4AB.DE.

What is company IPO date?

IPO date of AbbVie Inc. is 2016-05-17.

What is company current share price?

Current share price is 149.200 EUR.

What is stock market cap today?

The market cap of stock today is 263467804000.000.

What is PEG ratio in 2024?

The current -0.865 is -0.865 in 2024.

What is the number of employees in 2024?

In 2024 the company has 50000.